Acute myeloid leukemia (AML) is a molecularly diverse malignancy with a poor prognosis whose largest subgroup is characterized by somatic mutations in NPM1, which encodes nucleophosmin 1 . These mutations, termed NPM1c, result in cytoplasmic dislocation of nucleophosmin 1 and are associated with distinctive transcriptional signatures 2 , yet their role in leukemogenesis remains obscure. Here we report that activation of a humanized Npm1c knock-in allele in mouse hemopoietic stem cells causes Hox gene overexpression, enhanced self renewal and expanded myelopoiesis. One third of mice developed delayed-onset AML, suggesting a requirement for cooperating mutations. We identified such mutations using a Sleeping Beauty 3,4 transposon, which caused rapid-onset AML in 80% of mice with Npm1c, associated with mutually exclusive integrations in Csf2, Flt3 or Rasgrp1 in 55 of 70 leukemias. We also identified recurrent integrations in known and newly discovered leukemia genes including Nf1, Bach2, Dleu2 and Nup98. Our results provide new pathogenetic insights and identify possible therapeutic targets in NPM1c+ AML.
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Nucleophosmin has roles in several cellular processes, including ribo some biogenesis and centrosome duplication 5, 6 , for which it relies on its ability to shuttle between the nucleolus, nucleus and cytoplasm using subcellular localization signals 7 . This ability is impaired in 35% of AMLs as a result of NPM1c mutations 1 , which disrupt the Nterminal nucleolar localization signal of nucleophosmin and generate a nuclear export signal in its place 1, 8 . NPM1c mutations are mutually exclusive of fusion genes found in other types of AML 9 but frequently cooccur with activating mutations in FLT3 (ref. 1) or RAS genes 10 .
NPM1c is known to bind to and alter the subcellular distribution of several proteins, including HEXIM1, Fbw7γ, p19Arf and NFκB 8 ; however, the relevance of these interactions to AML is unknown 6, 8 . Selected transgenic mouse lines overexpressing NPM1c in myeloid progenitors have an increased incidence of mild myeloproliferative syndromes, but the meaning of this observation is unclear as these mice do not develop AML 11 .
To study the molecular, cellular and leukemogenic effects of NPM1c, we generated a conditional knockin mouse model of the most common form of NPM1c mutation, type A 1 . We confirmed that the human (NPM1 cA ) and 'humanized' mouse (Npm1 cA ) type A mutant proteins (Supplementary Fig. 1 ) showed the same subcellular localization (Fig. 1a) and then proceeded to modify the Npm1 locus in mouse embryonic stem cells. The conditional allele, Npm1 flox-cA , was designed to minimize interference with the native locus, as this could itself be leukemogenic 12 , but switch to the mutant allele, Npm1 cA , after CreloxP recombination (Fig. 1b) . We confirmed that after CreloxP recombination, Npm1 flox-cA/+ embryonic stem cells expressed the Npm1 cA mutant mRNA and protein (Fig. 1c,d ) and then established the Npm1 flox-cA/+ allele in mice, which were born at Mendelian ratios. However, the Npm1 cA allele was incompatible with normal embryonic development as crosses between Npm1 flox-cA/flox-cA mice and mice heterozygous for Stella-Cre, which mediates CreloxP recombination in the early embryo (P.L., data not shown), gave no doubletransgenic live offspring (0 out of 80 offspring) or embryos at embryonic day (E) 8 (n = 11), E10 (n = 10) and E12 (n = 23). By contrast, the offspring of Npm1 flox-cA/flox-cA ; Mx1-Cre + crosses were born at Mendelian ratios (Fig. 1e) .
To study the hemopoietic effects of Npm1 cA , we treated 5 to 8weekold Npm1 +/+ and Npm1 flox-cA/+ mice (hereafter collectively referred to as Npm1 WT ) and Npm1 flox-cA/+ ; Mx1-Cre + mice (hereafter referred to as Npm1 cA/+ ) with polyinosinicpolycytidylic acid (pIpC) and analyzed the mice 8 weeks later. We saw CreloxP recombina tion in >90% of bonemarrow-derived hemopoietic colonies from Npm1 cA/+ mice ( Supplementary Fig. 2 ), reflecting efficient recombi nation in hemopoietic stem cells (HSCs); Npm1 cA protein was detect able in Npm1 cA/+ hemopoietic tissues (Fig. 2a) Supplementary Fig. 3 ).
Npm1 cA/+ and Npm1 WT blood counts did not differ (Fig. 2c) , although Npm1 cA/+ mice had increased mean red cell and platelet volumes (Fig. 2d) . Bone marrow histomorphological examination revealed no detectable abnormalities or differences ( Supplementary  Fig. 4a ). Flow cytometric analysis of marrow cells showed no signifi cant differences in stem or progenitor cell compartment sizes (Fig. 2e,f and Supplementary Fig. 4b ). However, Npm1 cA/+ mice had increased numbers of Gr1+/Mac1+ myeloid cells and decreased numbers of late Bcells (B220+/CD19+) ( Fig. 2g-i) . Additionally, Npm1 cA/+ cells showed increased serial replating ability in methylcellulose, an in vitro surrogate for selfrenewing potential 13 (Fig. 2j) . There were no differences in levels of Gr1+/Mac1+ cell apoptosis or DNA damage ( Supplementary Fig. 4c-e) .
To study the leukemogenicity of Npm1 cA , we allowed 43 Npm1 cA/+ and 44 Npm1 WT mice to age. Npm1 cA/+ mice had a shorter over all survival compared to Npm1 WT mice (617 days compared to 769 days; P = 0.018) as a result of excess deaths due to AML (13 deaths compared to 0 deaths; P = 0.0001) (Fig. 2k,l) . Morphologically, AMLs showed maturation ('myeloid leukemia with maturation' 14 ) , and all five AMLs tested were Gr1+/Mac1+. Of 13 Npm1 cA/+ mice with AML, we found 6 to have coincidental nonextensive Blymphoid tumors. Compared to Npm1 cA/+ mice dying of nonhematological causes, mice with AML had enlarged livers (2.6 g compared to 1.8 g; P < 0.001) and spleens (1.3 g compared to 0.3 g; P < 0.001) and higher blood leukocyte counts (77.1/l compared to 7.0 × 10 6 /l; P = 0.006) (Supplementary Table 5 ). Also, two out of two AMLs tested were transplantable into sublethally irradiated syngenic mice (Supplementary Table 6 ). Finally, Npm1 cA/+ and Npm1 WT mice developed lymphoid tumors at the expected rate for their age and strain 15 and had similar rates of nonhematological mortality ( Fig. 2k and Supplementary Table 5) .
The above data show that Npm1c can initiate AML; however, the long latency reflects the need for additional mutations to be present as well. To identify cooperating mutations, we subjected Npm1 cA/+ mice to insertional mutagenesis with Sleeping Beauty 3 . We gener ated transgenic mice carrying approximately 80 copies of GrOnc, a new bifunctional PiggyBac/Sleeping Beauty transposon 16 capable of both gene activation and disruption (Fig. 3a,b and Supplementary  Fig. 5 ). GrOnc harbors the Graffi1.4 murine leukemia virus LTR, l e t t e r s which preferentially promotes myeloid rather than lymphoid leuke mia in predisposed backgrounds, an effect attributed to the LTR 17 . We crossed Npm1 flox-cA/+ , GrOnc, Mx1-Cre and conditional Rosa26 flox-SB transposase (Supplementary Fig. 6 (Fig. 3c) . However, mean survival was significantly shorter in the Npm1 cA/+ mice compared to Npm1 WT mice (99 versus 150 days; P = 0.001) (Fig. 3c) . We stud ied the first 121 mice (87 Npm1 cA/+ and 34 Npm1 +/+ mice) in detail and classified tumors by histological type (Supplementary Table 6 ), which we confirmed by flow cytometry in 18 leukemias. Compared to Npm1 +/+ mice, Npm1 cA/+ mice had a significantly higher fraction of AMLs (80.5% versus 26.5%; P = 0.00000002) and no Tcell leukemias (0% versus 17.6%; P = 0.00006) (Fig. 3d-f) . These findings indicate strong synergy between Npm1 cA and GrOnc in promoting myeloid leukemogenesis. In some mice, we identified a coincidental second tumor (leukemia and/or lymphoma in 19.8% and angiosarcoma in 3.3%) (Supplementary Table 7) .
To identify the genetic mutations collaborating with Npm1c to cause AML, we mapped the transposon integration sites in hemopoietic tumors from 87 Npm1 cA/+ and 34 Npm1 +/+ mice using barcoded splinkerette PCR and 454 sequencing. A total of 219,556 highquality reads mapped evenly throughout the genome, although, as expected for Sleeping Beauty 3,4 , we observed local hopping around the GrOnc donor site located at 30 Mb on chromosome 19 ( Supplementary  Fig. 8 ). We identified common insertion sites (CISs) for Npm1 cA/+ and Npm1 +/+ tumors using the kernel convolution method 18 and discarded those mapping within 2 Mb of the donor site. The only other CIS on chromosome 19 involved Pten, located at 32.8 Mb, which makes its importance uncertain. The CIS sets in Npm1 cA/+ and Npm1 +/+ tumors included several known and many new putative leukemia genes (Fig. 4a and Supplementary Figs. 8,9 ). The two sets overlapped but were clearly different, indicating that distinct molecu lar pathways operated in the two groups.
In the Npm1 cA group, the most striking finding was the identification of activating integrations upstream of Csf2 (which encodes GMCSF) in 48.3% of leukemias, associated with LunSD-Csf2 fusion transcripts, Csf2 mRNA overexpression (Fig. 4b-d) and increased levels of GMCSF in leukemic cell supernatants (P = 0.0007, Supplementary Table 8) . We studied transposon integrations in singlecell-derived methylcellulose colonies from three Csf2+ AMLs and found that over 90% of colony forming unit (CFU) colonies (11 out of 12, 12 out of 12 and 19 out of 20 mice in the three colonies, respectively) carried 
Csf2 insertions. We proceeded to map transposon integrations in three such colonies from AML 36 and found that individual colonies carried 67-90 independent integrations each, yet only two integrations were shared between them: those involving Csf2 and the myeloid oncogene Myst4 (also called Moz) (Fig. 4e) . This is the first study of the subclonal composition of transposonderived malignancies and shows that, if the transposase remains active, trans posons are continuously remobilized, gen erating a highly heterogeneous population, except for a small number of key insertions, which may be the leukemia 'drivers' . We went on to study transposon integrations in leukemias developing in irradiated recipients transplanted with AMLs 26 and 38. We found that Csf2 insertions persisted in all five recipi ent mice studied (Supplementary Table 5) , whereas the vast majority (>98%) of other insertions were lost. These data strongly indicate that Csf2 insertions are critical to the growth of these leuke mias and thus persist during leukemic evolution and propagation, whereas 'passenger' insertions are lost. Csf2 can behave as a myeloid oncogene in mice when activated by endogenous retroviruses 19 , and autocrine GMCSF production has been reported to drive the growth of human AML blasts in vitro 20, 21 and this is usually, albeit not always, inhibited by GMCSF antibodies 20 .
Other important CISs included Flt3 (Fig. 4f) , a gene frequently comutated in human NPM1c+ AML, and Nup98 (Fig. 4g) , encoding a key component of the nuclear pore and a leukemogenic fusion gene partner not previously identified as a retroviral or transposon CIS. NUP98 fusion proteins can directly interfere with nucleocytoplasmic transport of NPM1c 22 
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Csf2 normalized expression (Fig. 5a and Supplementary Fig. 10 ).
Cooccurrence analysis of CIS genes from Npm1 cA/+ AMLs showed that Csf2 integrations were mutually exclusive of integrations in Flt3 (P = 0.002) and Rasgrp1 (P = 0.008) (Fig. 5a and Supplementary  Fig. 11 ). This was also true for Kras, but the comparison did not reach statistical significance (P = 0.12). These observations suggest that these genes provide alternative proliferation signals that complement Npm1c in promoting cellular transformation. Notably, Rasgrp1, previously associated with Tlymphoblastic leukemia in retroviral mutagenesis screens 23 , was recently identified as a drug resistance gene in another mouse model of AML 24 . Also, Hox gene overexpression persisted in Npm1 cA/+ transposonderived AMLs, irrespective of transposon insertions, suggesting that the molecular effects of Npm1c mutations remained operative in leukemic cells (Fig. 5b) . Hoxa7 and Hoxa9 are frequently targeted by retroviruses in BXH2 myeloid leukemias 25 and mediate leukemic transformation by MLL oncoproteins 26 . Also, in line with our findings, Hoxa9 −/− mice show defects in maturing myeloid and Blymphoid cells but not early progenitors 27 . Overall, this makes it highly plausible that overexpression of Hox genes mediates the leuke mogenic effects of NPM1c, particularly as expression levels seen in our mice are comparable to those in human AMLs 28 .
Taken together, our data show that Npm1c mutations are AML initiating lesions that cause Hox gene overexpression, impart increased self renewal to and prime hemopoietic stem and progenitor cells to leukemic transformation by activation of a narrow set of pro proliferative molecules and pathways, usually in combination with mutations in transcriptional regulators (Fig. 5c and Supplementary  Tables 1-3) . Observations from wholegenome sequencing studies are generating data in support of such a model in this and other subgroups of AML with a normal karyotype 10, 29 . Also, our data explain other important features of human NPM1c+ AML, including a consistent negativity for the primitive marker CD34 (the effects of Npm1 cA are most noticeable on later progenitors) and a failure to observe NPM1c mutations in the human germline (embryonic lethality). Finally, our approach to define the effects of a mutation in isolation and then map its collaborative oncogenic pathways provides a model for the study of other human cancerassociated mutations and can be used to complement and help decipher recent and impending whole cancer genome sequencing studies. Gene name   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69 
